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ABSTRACT
Salmonella typhimurium A1-R (S. typhimurium A1-R) attenuated by leu and arg 
auxotrophy has been shown to target multiple types of cancer in mouse models. In the 
present study, toxicologic and biodistribution studies of tumor-targeting S. typhimurium 
A1-R and S. typhimurium VNP20009 (VNP 20009) were performed in a syngeneic 
tumor model growing in immunocompetent BALB/c mice. Single or multiple doses of 
S. typhimurium A1-R of 2.5 × 105 and 5 × 105 were tolerated. A single dose of 1 × 106 
resulted in mouse death. S. typhimurium A1-R (5 × 105 CFU) was eliminated from the 
circulation, liver and spleen approximately 3-5 days after bacterial administration via 
the tail vein, but remained in the tumor in high amounts. S. typhimurium A1-R was 
cleared from other organs much more rapidly. S. typhimurium A1-R and VNP 20009 
toxicity to the spleen and liver was minimal. S. typhimurium A1-R showed higher 
selective targeting to the necrotic areas of the tumors than VNP20009. S. typhimurium 
A1-R inhibited the growth of CT26 colon carcinoma to a greater extent at the same 
dose of VNP20009. In conclusion, we have determined a safe dose and schedule of S. 
typhimurium A1-R administration in BALB/c mice, which is also efficacious against tumor 
growth. The results of the present report indicate similar toxicity of S. typhimurium 
A1-R and VNP20009, but greater antitumor efficacy of S. typhimurium A1-R in an 
immunocompetent animal. Since VNP2009 has already proven safe in a Phase I clinical 
trial, the present results indicate the high clinical potential of S. typhimurium A1-R.
INTRODUCTION
For more than 200 years, there have been reports that 
cancer patients went into remission after recovering from 
bacterial infections [1]. From the late 19th to early 20th 
century, William Coley, an American physician, treated 
cancer patients with both live and heat-killed bacteria such 
as Streptococcus pyogenes and Serratia marcescens as first-
line therapy for sarcoma and lymphoma. The combination 
of Coley’s heat-killed bacteria was referred to as “Coley’s 
toxins, which remained in clinical use for sarcoma patients 
until 1963 [1]. Since 1976, BCG (Bacillus Calmette-Guerin) 
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bacteria have been used to treat superficial bladder cancer 
[2], which is still in clinical use [3].
There has been a great resurgence in preclinical 
research on bacterial therapy of cancer in the last 20 years 
[4]. Salmonella species are the most extensively studied 
bacteria in the field of tumor targeting. They are Gram-
negative facultative-anaerobic bacteria that can grow and 
replicate inside host cells. Some Salmonella strains can 
preferentially colonize solid tumors [5–8].
Salmonella typhimurium VNP20009 (VNP20009) 
is attenuated with a lipid A–mutation (msbB), purine 
auxotrophy (purI) and amino acid autotrophy [9]. 
In a Phase I clinical trial on patients with metastatic 
melanoma and renal-cell carcinoma in the United 
States, VNP20009 was not toxic but poorly colonized 
the patients’ tumors, perhaps because it was over 
attenuated [10]. At the highest tolerated dose, some 
tumor colonization was observed [10].
Another strain of S. typhimurium A1-R, auxotrophic 
for leu-arg has been developed by our laboratory. S. 
typhimurium A1-R was effective against primary and 
metastatic tumors as monotherapy in nude mouse models 
of major cancers, including prostate [8, 11], breast [12–
14], lung [15, 16], pancreatic [17–21], ovarian [22, 23] 
stomach [24], and cervical cancer [25]. In addition, S. 
typhimurium A1-R was effective against patient-derived 
orthotopic models (PDOX) of pancreatic cancer [17, 21], 
sarcoma [26–28] and melanoma [29–32].
Tumors with a high degree of vascularity were more 
sensitive to S. typhimurium A1-R, and vascular destruction 
appears to play a role in S. typhimurium A1-R antitumor 
efficacy [16].
In the present report, we compare efficacy, tumor 
targeting and toxicity of S. typhimurium A1-R and 
VNP20009, since VNP20009 has been tested to be safe in 
a Phase I clinical trial [10].
RESULTS AND DISCUSSION
Correlation between optical sensitivity and 
colony counting to quantitate bacteria
In order to determine viable bacterial counts, we 
analyzed the relationship between the OD600 value and 
bacteria colony forming units (CFU) on LB agar. A linear 
relationship between OD600 and CFU was observed for S. 
typhimurium A1-R: Y = 20.141x + 2.0578, R2 = 0.9473) 
(Figure 1).
Effect of a single-dose S. typhimurium A1-R on 
body weight of non-tumor-bearing BALB/c mice
Six- to 8-week-old BALB/c mice without tumors, 
with an average body weight 20 to 22 gram, were used in 
the study. A single-dose of S. typhimurium A1-R at 1 × 105 
- 5 × 105 CFU/mouse was administred i.v. Acute weight 
loss of 10% to 20% from day 0 was observed in all cohorts. 
However, body weight began recover by day 6. However, 
1 × 106 CFU/mouse did cause severe weight loss (Figure 
2A, 2B). No signs of delayed toxicity were observed. 
S. typhimurium A1-R doses at 1 × 105 and 5 × 105 CFU did 
not cause mouse death, but 1 × 106 CFU did (Figure 2C, 2D).
Effect of a single dose of S. typhimurium A1-R on 
body weight of tumor-bearing BALB/C mice
Single doses of 1 × 105, 5 × 105 and 1 × 106 were 
given to BALB/c mice bearing subcutaneous CT26 
murine colon tumors. The body weight loss in the tumor-
bearing mice was less than in the normal mice. The tumor-
bearing mice which were given the 1 × 106 CFU dose of 
S. typhimurium A1-R rapidly recovered unlike the non-
tumor bearing mice (Figure 3A, 3B). However, although 
no deaths were observed at the two lower doses, the 1 × 
106 CFU dose caused death (Figure 3C, 3D).
Effect of multiple doses of S. typhimurium A1-R 
on the body weight of tumor-bearing mice
Based on the single-dose toxicologic results, we also 
assessed the toxicity of multiple doses of S. typhimurium 
A1-R compared with PBS administered to tumor-bearing 
mice (Figure 4). Weekly doses of S. typhimurium A1-R 
at 2.5, or 5 × 105 CFU/mouse, were administered for 3 
weeks. The 2.5 × 105 CFU weekly doses did not cause 
noticeable weight loss. The 5 × 105 CFU/mouse caused a 
body weight loss by day-4 which was recovered by day-
11. Weekly doses of VNP20009 at 5 × 105 or 1 × 106 CFU/
mouse were administered for 3 weeks without noticeable 
weight loss.
Clearance of S. typhimurium A1-R from the 
circulation
To quantitatively assess the clearance of bacteria 
from the circulation, GFP-labeled S. typhimurium A1-R 
(S. typhimurium A1-R-GFP) was intravenously injected 
into non-tumor-bearing and tumor-bearing BALB/c 
mice. S. typhimurium A1-R-GFP in the blood was 
collected, cultured, and counted at various times after 
injection using three mice per time point. Greater than 
95% of the bacteria were cleared from the circulation 
within 1 day in non-tumor-bearing mice, and the number 
of CFU fell to barely detectable levels over the next 7 
days (Figure 5). Bacteria in tumor-bearing mice were 
cleared more slowly (Figure 5).
Biodistribution of bacteria
To determine the distribution of bacteria, normal 
and tumor-bearing BALB/c mice were injected with 
S. typhimurium A1-R GFP. Organs and tumors were 
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Figure 2: Effect of a single dose of S. typhimurium A1-R on body weight of non-tumor-bearing mice. Normal BALB/c 
mice, aged 6 weeks, were injected with S. typhimurium A1-R at different doses in 100 μl PBS into the tail vein. Body weight was measured 
using an electronic scale. (A) Body weight curve for male female (n = 5). (B) Body weight curve for male mice. n = 5 mice for each group. 
(C) Survival time curve for female mice (n = 5). (D) Survival time curve for male mice. n = 5 mice for each group.
Figure 1: Comparison of OD600 and colony counting to quantify bacteria. GFP-expressing S. typhimurium A1-R-GFP was 
grown overnight in LB medium and then diluted 1:10 in LB medium. Bacteria were harvested at late-log phase, washed with PBS, and then 
diluted in PBS. OD600 measurements were performed on a spectrophotometer at dilutions of 10×. Each dilution analysis of bacteria in PBS 
was plated and cultured overnight in LB agar and the number of resulting bacterial colonies was counted. Regression line demonstrates the 
correlation between colony-forming units with (CFU) bacteria and OD600.
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Figure 3: Effect of a single dose of S. typhimurium A1-R on body weight of tumor-bearing mice. BALB/c mice bearing 
CT26 tumors with a tumor volume of 100 mm3 were treated with S. typhimurium A1-R at different doses in 100 μl PBS into the tail vein. 
Body weight was measured using an electronic scale. (A) Body weight curve for female mice (n = 5). (B) Body weight curve for male 
mice. n = 5 mice for each group. (C) Survival curve for female mice (n = 5). (D) Survival curve for male mice. n = 5 mice for each group.
Figure 4: Effect of multiple doses of S. typhimurium A1-R and S. typhimurium VNP20009 on body weight of tumor-
bearing mice. Mice were treated with 2.5 × 105 CFU, and 5 × 105 CFU S. typhimurium A1-R weekly or 5 × 105 and 1 × 106 CFU 
VNP20009 weekly × 3. All treatments were administered i.v.
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collected, homogenized and S. typhimurium A1-R was 
cultured on LB agar. The number of CFU was counted 
from organs starting 1 hour after injection. Bacteria 
colonies from organs and tumors were subsequently 
observed by fluorescence microscopy. In non-tumor-
bearing mice, significant S. typhimurium A1-R-GFP 
colonies from organs were present at 1 h after injection, 
but were undetectable 1week later. The largest amount of 
S. typhimurium A1-R-GFP was present in the liver and 
spleen, but was cleared by 7 days. The other organs were 
cleared by 3 days (Figure 6A).
In the tumor-bearing mice, S. typhimurium A1-R-
GFP in tumors survived much longer than in the normal 
organs (Figure 6B).
S. typhimurium A1-R-GFP and VNP20009-RFP 
were isolated from the viable and necrotic tumor regions 
and cultured in LB agar. S. typhimurium A1-R survived 
in tumor necrotic regions more than VNP20009 at day-7 
when the bacteria were administered i.v. (p<0.01) (Figure 
7). FP Fluorescent colonies of S. typhimurium A1-R-GFP 
isolated from the tumor, spleen and liver at various time 
points were imaged. 
Fluorescent colonies are seen derived from the 
tumor at all time points from 1 hour to day 7. Fluorescent 
colonies can be seen isolated from the liver and spleen only 
at 1 hours and day 1 and not at day 3 and day 7 (Figure 8).
Effect of S. typhimurium A1-R on organ weight 
and histology
Each mouse received a single intravenous injection 
of S. typhimurium A1-R (5 × 105 CFU). In non-tumor-
bearing mice, only the spleen significantly increased in 
weight after treatment with S. typhimurium A1-R (5 × 105 
CFU) beginning at day 3 (Figure 9A).
In female BALB/c mice bearing subcutaneous 
CT26 mouse colon tumors, S. typhimurium A1-R (5 
× 105 CFU) treatment also caused the spleen to gain 
significant weight beginning at day 7, compared to 
control mice (Figure 9B).
Histopathologic analysis of liver and spleen 
at day 3 post-treatment of S. typhimurium A1-R or 
VNP20009 showed pathological changes in both organs 
(Figure 9C).
Efficacy of S. typhimurium A1-R and VNP20009 
on the CT26 colon tumor in BALB/c mice
S. typhimurium A1-R reduced tumor growth to a 
greater extent than VNP20009 (p<0.05). S. typhimurium 
A1-R at 5 × 105 CFU arrested tumor growth. VNP20009 
at 1 × 106 CFU and S. typhimurium A1-R at 2.5 × 105 CFU 
both slowed tumor growth to a similar extent, but could 
Figure 5: Bacteria clearance from blood circulation. S. typhimurium A1-R (5 × 105 CFU/100 μl PBS/mouse) were injected into 
non-tumor-bearing mice or CT26 tumor-bearing BALB/c mice. Bacteria in 100 μl of blood were counted after overnight culture in LB agar. 
Values in both graphs represent the mean (with standard deviation) of at least three mice per time point.
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Figure 6: Distribution of S. typhimurium A1-R. S. typhimurium A1-R (5 × 105 CFU/100 μl PBS/mouse) were injected into normal 
(A) or CT26 tumor-bearing BALB/c mice (B). Tissues were removed at time points indicated and homogenized. Homogenates from 
isolated from the tumors and organs were cultured in LB agar. At least three mice were evaluated per time point.
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Figure 7: S. typhimurium A1-R and VNP20009 were isolated from the necrotic areas of tumors at various time points.
Figure 8: Fluorescence images of S. typhimurium A1-R-GFP isolated from the tumor, spleen and liver at various time 
points on LB agar.
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Figure 9: Toxicity of S. typhimurium A1-R on organ weight and S. typhimurium A1-R and S. typhimurium VNP20009 
on organ histology. (A) Non-tumor-bearing BALB/c mice were treated with 5 × 105 CFU/100 μl PBS/mouse. Liver and spleen were 
removed, collected and weighed at different time points indicated above. N = 6 at each time point. (B) BALB/c mice bearing CT26 tumors 
with a tumor volume of (100 mm3) were treated with 5 × 105 CFU S. typhimurium A1-R 100 μl PBS/mouse. Liver and spleen were removed, 
collected and weighed at different time points indicated above. N = 6. (C) Hematoxylin and eosin (H&E)-stained sections of spleens and 
livers of control, S. typhimurium A1-R-treated and VNP20009-treated non-tumor-bearing mice.
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Figure 10: Antitumor efficacy of S. typhimurium and VNP20009. CT26 cells (2 × 106/100 μl/mouse) were injected into the 
right flank of BALB/c mice. When the average tumor volume reached approximately 100 mm3, S. typhimurium A1-R (2.5 or 5 × 105 
CFU) or VNP20009 (5 or 10 × 105 CFU) were injected into the tail vein once a week for three times. Primary tumor sizes were measured 
with a caliper. (A) Tumor growth curves comparing S. typhimurium A1-R or S. typhimurium VNP at both doses. (B) Tumor weight in S. 
typhimurium A1-R- and S. typhimurium VNP20009-treated mice, compared to control mice (*p<0.05; **p<0.01) at day 19 after treatment. n 
= 5 mice for each group. (C) Tumor histology shown in hematoxylin and eosin (H&E)-stained sections. (a) Tumor treated with VNP20009; 
(b) tumor treated with S. typhimurium A1-R.
not arrest tumor growth (Figure 10A). VNP20009 at 1 × 
106 CFU caused extensive mouse body weight loss, unlike 
the effective 5 × 105 CFU dose of S. typhimurium A1-R 
(Figure 4).
Tumor weight was measured on day 19. S. 
typhimurium A1-R at 2.5 × 105 CFU (p<0.05) and 5 × 105 
CFU (p<0.01) decreased tumor weight. VNP20009 at 1 × 
106 CFU inhibited tumor weight (p<0.05), but VNP20009 
at 5 × 105 CFU did not inhibit tumor weight (Figure 10B). 
VNP20009 at 1 × 106 CFU caused severed body weight 
loss, as mentioned above (Figure 4). Both S. typhimurium 
A1-R and VNP20009, treated tumor contained viable 
nuclei, small areas of necrosis, with accompanying acute 
inflammation.
Previously-developed concepts and strategies of 
highly-selective tumor targeting can take advantage of 
molecular targeting of tumors, including tissue-selective 
therapy which focuses on unique differences between 
normal and tumor tissues [33–38].
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MATERIALS AND METHODS
Cell lines and other reagents
Murine CT26 colon cancer cells were obtained 
from ATCC (The American Type Culture Collection) 
and grown in RPMI 1640 Medium (Invitrogen, Carlsbad, 
CA) supplemented with 10% fetal bovine serum (FBS; 
HyClone, Logan City, UT) at 37°C with 5% CO2.
Mice
Athymic nu/nu nude mice (AntiCancer Inc., 
San Diego, CA), 4–6 weeks old, were used in this 
study. Animals were housed in a barrier facility on a 
high efficacy particulate arrestance (HEPA)-filtered 
rack under standard conditions of 12-hour light/dark 
cycles. The animals were fed an autoclaved laboratory 
rodent diet. All mouse surgical procedures and imaging 
were performed with the animals anesthetized by 
subcutaneous injection of a ketamine mixture (0.02 ml 
solution of 20 mg/kg ketamine, 15.2 mg/kg xylazine, 
and 0.48 mg/kg acepromazine maleate). The response 
of animals during surgery was monitored to ensure 
adequate depth of anesthesia. The animals were 
observed on a daily basis and humanely sacrificed 
by CO2 inhalation if they met the following humane 
endpoint criteria: severe tumor burden (more than 20 
mm in diameter), prostration, significant body weight 
loss, difficulty breathing, rotational motion and body 
temperature drop. All animal studies were conducted in 
accordance with the principles and procedures outlined 
in the National Institutes of Health Guide for the Care 
and Use of Animals under Assurance Number A3873-1.
Preparation of S. typhimurium A1-R
GFP-expressing S. typhimurium A1-R bacteria 
(AntiCancer Inc.,) were grown overnight on LB medium 
(Fisher Sci., Hanover Park, IL, USA) and then diluted 
1:10 in LB medium. Bacteria were harvested at late-
log phase, washed with PBS, and then diluted in PBS 
[8, 11, 12].
Comparison of OD600 and colony counting to 
quantify bacteria
GFP-expressing S. typhimurium A1-R were grown 
overnight in LB medium and then diluted 1:10 in LB 
medium. Bacteria were harvested at late-log phase, 
washed with PBS, and then serial diluted 10-fold for six 
times in PBS. OD600 measurements were performed on a 
spectrophotometer. Dilutions of bacteria were plated on 
LB agar and incubated at 37°C overnight. Colonies were 
counted under fluorescence microscopy to determine 
colonr forming units (CFU/ml) at each time point.
Tumor inoculation
Murine CT26 colon cancer cells (2×106) were 
injected subcutaneously into the right flank of BALB/c 
mice. Tumor volume was calculated as length × width2 
× 0.5. In general, 10–14 days were required for tumors to 
reach the target size of 100 mm3 for treatment initation.
Dose-tolerance experiments
The dose-tolerance relationship was examined in 
BALB/c mice for a single bolus or multiple doses once 
weekly for 3 consecutive weeks of S. typhimurium A1-R 
or VNP20009. Animal weights were compared with day 
0 (first day of treatment administration) to determine 
percentage weight change. Mice were sacrificed at 
either 25% weight loss from day 0 or at the end of the 
observation period, which ever came first.
After administration of S. typhimurium A1-R or 
VNP20009 or control treatments, mice were closely 
monitored and weighed daily for 8 days, then at day 10 and 
12, and twice weekly until the end of the observation period. 
At this stage, the animals were euthanized by CO2 inhalation.
Biodistribution of S. typhimurium A1-R-GFP
At various time points after injection of S. 
typhimurium A1-R, mice were sacrificed by CO2 narcosis 
at 1 h, 1 day, 3 days, 7 days, 14 days and 28 days post-
injection, and their blood (0.1 ml), brain, heart, lungs, liver, 
spleen, kidneys, muscle, bone, small and large intestines, 
and tumor were harvested. Tissues were removed, 
weighed, and homogenized in phosphate buffered saline 
(PBS), at 2 ml per 200 mg of tissue using an homogenizer 
(Fisher Scientific, USA) at a speed of ~24,000 rpm for 30-
60 s. The resulting suspension was serial diluted by 10× 
dilutions in PBS and carefully spread onto LB agar. Blood 
was obtained from intracardiac puncture and mixed with 
9 volumes of PBS, after which a 100 μl suspension was 
spread on LB agar plates. LB agar plates were incubated 
for 18 h at 37°C. Following incubation, plates were 
removed from the incubator and colonies were counted. 
At least three mice were used for each time point. S. 
typhimurium A1-R-GFP colonies were visualized with 
an Olympus OV100 Small Imaging System with a CCD 
camera [39].
Histological analysis
Fresh tumor and organ samples were fixed in 10% 
formalin and embedded in paraffin before sectioning and 
staining. Tissue sections (5 μm) were deparaffinized in 
xylene and rehydrated in an ethanol series. Hematoxylin and 
eosin (H &E) staining was performed according to standard 
protocols. Histological examination was performed with a 
BHS System Microscope (Olympus Corporation, Tokyo, 
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Japan). Images were acquired with INFINITY ANALYZE 
software (Lumenera Corporation, Ottawa, Canada) [28].
Anti-tumor efficacy
BALB/c mice bearing CT26 murine colon 
carcinoma xenografts were administered S. typhimurium 
A1-R or VNP20009 (i.v) with weekly doses indicated in 
Figure 10. Mice were monitored and weighed as described 
in the toxicity studies. Tumors were measured twice 
weekly using calipers along the x and y plane of the tumor. 
Tumor volume was determined using the formula volume 
= a x (b2)/2, where a is the largest diameter and b is the 
smallest diameter. Antitumor assessment of treatments was 
determined by reduction in tumor growth rate compared 
with controls.
Statistical analysis
All statistical analyses were performed using 
SYSTAT 12.0 (SYSTAT, Inc., Chicago, IL, USA). The 
experimental data are expressed as the mean ± SD. The 
two-tailed Student’s t-test was used for statistical analysis, 
with α equal to 0.05. P<0.05 was considered statistically 
significant.
CONCLUSION
S. typhimurium A1-R has a similar toxicity pattern 
as VNP20009 which was previously determined to be safe 
in a Phase I clinical trial. However, S. typhimurium A1-R 
had significantly greater tumor targeting and anti-tumor 
efficacy than VNP20009. The results of the present study, 
therefore, indicate the promising clinical potential of S. 
typhimurium A1-R.
Bacterial therapy offers many advantages over 
conventional chemotherapy, including, but not limited 
to tumor-targeting, ability to deliver therapeutic cargoes, 
does not depend entirely on the tumor vascular system to 
reach the tumor since bacteria are motile, can stimulate the 
immune system against the tumor, can serve as adjuvant 
treatment after surgery to eliminate residual disease and 
can enhance chemotherapy by decoying quiescent drug-
resistant cancer cells in tumors to attempt to cycle, thereby 
becoming sensitive to chemotherapy [4].
With regard to bacterial labeling, small molecular 
fluorescent probes or radionuclides may offer advantages 
over GFP to label S. typhimurium A1-R regarding 
translation to the clinic [40, 41]. Whether S. typhimurium 
A1-R can pass the blood-brain barrier is still an open 
question. Although, S. typhimurium A1-R was found 
at early time-points in the brain in the present study, it 
is possible that bacteria were actually from brain blood 
vessels in which the bacteria have not passed to the brain 
tissue itself. On the other hand, S. typhimurium A1-R 
prevented brain metastasis in a breast cancer mouse model 
[14]. It is not clear if the bacteria had to cross the blood-
brain barrier for this anti-brain-metastasis efficacy. Future 
experiments will address this point.
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